World-renowned Scientist, Described as the Edison of Medicine by Forbes Magazine, Dr. Robert Langer Joins Daré Bioscience Sc...
March 29 2019 - 7:00AM
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health
innovation, announced that Dr. Robert Langer, co-inventor of Daré‘s
novel, segmented intravaginal ring (IVR) drug delivery technology
and one of the 10 Institute Professors at the Massachusetts
Institute of Technology (MIT) joined the company’s Scientific
Advisory Board.
In his work at MIT, Dr. Langer’s research focuses on the
integration of medicine, materials science and chemical
engineering. His pioneering work in biotechnology began when he
joined Dr. Judah Folkman’s cancer researcher lab at the Children's
Hospital Boston. Their combined efforts led to the design of a
novel delivery system for a tumor inhibitor using a synthetic
polymer system that was directly implanted into the tumor. While at
Dr. Folkman’s lab, Dr. Langer pursued a second line of research to
identify polymers that would permit the gradual timed release of
medication within the body.
“I have a deep passion and commitment for transforming science
into life-saving and life-improving inventions and I am delighted
to be a member of Daré’s Scientific Advisory Board,” said Dr.
Langer. “The polymer-based segmented IVR delivery platform is a
truly innovative approach that is uniquely designed for women. I am
looking forward to working closely with the scientific and medical
team at Daré to help advance the many important applications of the
IVR platform as well as advising on broader strategic and research
initiatives across their novel women’s health portfolio.”
Currently, Dr. Langer is the most cited engineer in history. He
has authored over 1,400 articles, and holds over 1,350 issued and
pending patents worldwide. He served as a member of the United
States Food and Drug Administration’s SCIENCE Board, the FDA’s
highest advisory board, from 1995 to 2002, and as its Chairman from
1999 to 2002.
“We are truly honored to have Dr. Langer join our distinguished
board of scientific advisors,” said Sabrina Martucci Johnson,
President and CEO of Daré Bioscience. “We believe Dr. Langer’s
contributions to science and technology are unparalleled and we
feel extremely fortunate to have him advising the company on our
IVR drug delivery platform as well as our other novel pipeline
initiatives.”
Dr. Langer has received over 220 major awards and is one of
seven individuals to have received both the United States National
Medal of Science, in 2006, and the United States National Medal of
Technology and Innovation, in 2011. Dr. Langer also received the
2002 Charles Stark Draper Prize, considered the equivalent of the
Nobel Prize for engineers, and the 2008 Millennium Prize, the
world’s largest technology prize. In 2012 he received the Priestley
Medal, the highest award of the American Chemical Society, and in
2013 he was awarded the Wolf Prize in Chemistry. In 2015 he
received the Queen Elizabeth Prize for Engineering. Dr. Langer
received his Bachelor’s Degree from Cornell University in 1970 and
his Sc.D. from the Massachusetts Institute of Technology in 1974,
both in Chemical Engineering.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company
committed to the advancement of innovative products for women’s
health. The company’s mission is to identify, develop and bring to
market a diverse portfolio of differentiated therapies that expand
treatment options, improve outcomes and facilitate convenience for
women, primarily in the areas of contraception, vaginal health,
sexual health, and fertility.
Daré’s product portfolio includes potential first-in-class
candidates in clinical development: Ovaprene®, a non-hormonal,
monthly contraceptive intravaginal ring; Sildenafil Cream, 3.6%, a
novel cream formulation of sildenafil to treat female sexual
arousal disorder utilizing the active ingredient in Viagra®;
DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2%
to treat bacterial vaginosis via a single application; and
DARE-HRT1, a combination bio-identical estradiol and progesterone
intravaginal ring for hormone replacement therapy following
menopause. To learn more about Daré’s full portfolio of women’s
health product candidates, and mission to deliver differentiated
therapies for women, please visit www.darebioscience.com.
Daré may announce material information about its finances,
product candidates, clinical trials and other matters using its
investor relations website
(http://ir.darebioscience.com), SEC filings, press
releases, public conference calls and webcasts. Daré will use
these channels to distribute material information about the
company, and may also use social media to communicate important
information about the company, its finances, product candidates,
clinical trials and other matters. The information Daré posts
on its investor relations website or through social media channels
may be deemed to be material information. Daré encourages
investors, the media, and others interested in the company to
review the information Daré posts on its investor relations
website (https://darebioscience.gcs-web.com/) and to follow
these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any
updates to the list of social media channels the company may use to
communicate information will be posted on the investor relations
page of the company's website mentioned above.
Contacts:
Investors on behalf of Daré Bioscience, Inc.: Alex Gray
Burns McClellan agray@burnsmc.com 212-213-0006
OR
Media on behalf of Daré Bioscience, Inc.: Amanda Guisbond
Canale Communications amanda@canalecomm.com 781-405-8775
Source: Daré Bioscience
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2024 to May 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From May 2023 to May 2024